Denali Therapeutics

$59.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.76 (-2.88%) As of 5:56 PM UTC today

Why Robinhood?

You can buy or sell DNLI and other stocks, options, and ETFs commission-free!

About DNLI

Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA. The listed name for DNLI is Denali Therapeutics Inc. Common Stock.

CEO
Ryan J. Watts
Employees
291
Headquarters
San Francisco, California
Founded
2013
Market Cap
7.48B
Price-Earnings Ratio
96.70
Dividend Yield
—
Average Volume
819.14K
High Today
$62.73
Low Today
$58.51
Open Price
$61.68
Volume
147.44K
52 Week High
$93.94
52 Week Low
$12.39

DNLI Earnings

-$0.61
$0.23
$1.07
$1.91
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
$1.91 per share

You May Also Like

ILF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure